Skip to main content
Premium Trial:

Request an Annual Quote

ERS Genomics, Applied Biological Materials Ink Gene Editing Licensing Agreement

NEW YORK – Irish biotechnology company ERS Genomics said on Thursday that it has reached a nonexclusive licensing agreement with Canadian life sciences firm Applied Biological Materials (ABM).

The agreement grants ABM access to ERS’s CRISPR-Cas9 patent portfolio. Financial details of the deal were not disclosed.

Based in Dublin, ERS Genomics was cofounded by Nobel Prize laureate for gene editing Emmanuelle Charpentier and holds over 100 patents worldwide as part of the Charpentier, the University of California, and the University of Vienna (collectively CVC) portfolio. A license from ERS provides complete access to the company’s CVC portfolio, which includes more than 55 patents in the US covering the use of CRISPR-Cas9 gene editing in eukaryotic cells, ERS said.

"With this new relationship, we are expanding our gene editing capabilities and envision broader usage of CRISPR-Cas9 in revolutionizing biotechnology and research into novel, new disease treatments," ABM CEO Peter Li said in a statement.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.